The human NTG model of migraine in drug discovery and development

References

• Ashina MM, Ropper AH. N Engl J Med. 2020;383(19):1866–1876. Migraine. doi: 10.1056/NEJMra1915327
   PubMed Web of Science ®Google Scholar
• Ashina M, Hansen JM, Á Dunga BO, et al. Human models of migraine - short-term pain for long-term gain. Nat Rev Neurol. 2017;13(12):713–724. doi: 10.1038/nrneurol.2017.137
   PubMed Web of Science ®Google Scholar
• Russell MB, Rasmussen BK, Brennum J, et al. Presentation of a new instrument: the diagnostic headache diary. Cephalalgia. 1992;12(6):369–374. doi: 10.1111/j.1468-2982.1992.00369.x
   PubMed Web of Science ®Google Scholar
• Headache classification committee of the International Headache Society (IHS) the international classification of headache disorders, 3rd edition. Cephalalgia. 2018;38(1):1–211. doi: 10.1177/0333102417738202
   PubMed Web of Science ®Google Scholar
• Ashina M, Terwindt GM, Al-Karagholi MA, et al. Migraine: disease characterisation, biomarkers, and precision medicine. Lancet. 2021;397(10283):1496–1504. doi: 10.1016/S0140-6736(20)32162-0
   PubMed Web of Science ®Google Scholar
• Ashina M, Hansen JM, Olesen J. Pearls and pitfalls in human pharmacological models of migraine: 30 years’ experience. Cephalalgia. 2013;33(8):540–553. doi: 10.1177/0333102412475234
   PubMed Web of Science ®Google Scholar
• Olesen J. The role of nitric oxide (NO) in migraine, tension-type headache and cluster headache. Pharmacol Ther. 2008;120(2):157–171. doi: 10.1016/j.pharmthera.2008.08.003
   PubMed Web of Science ®Google Scholar
• Hansen HJ, Drewes VM. The nitroglycerine ointment test – a double-blind examination. Danish Med Bull. 1970;17(8):226–229.
   PubMedGoogle Scholar
• Sicuteri F, Del Bene E, Poggioni M, et al. Unmasking latent dysnociception in healthy subjects. Headache. 1987;27(4):180–185. doi: 10.1111/j.1526-4610.1987.hed2704180.x
   PubMed Web of Science ®Google Scholar
• Iversen HK, Nielsen TH, Tfelt-Hansen P, et al. Lack of tolerance of headache and radial artery diameter during a 7 hour intravenous infusion of nitroglycerin. Eur J Clin Pharmacol. 1993;44(1):47–50. doi: 10.1007/BF00315279
   PubMed Web of Science ®Google Scholar
• Iversen HK, Holm S, Friberg L. Intracranial hemodynamics during intravenous nitroglycerine infusion. Cephalalgia. 1989;9(suppl 10):84–85. doi: 10.1177/0333102489009S1046
   Google Scholar
• Olesen J, Iversen HK, Thomsen LL. Nitric oxide supersensitivity. A possible molecular mechanism of migraine pain. Neuroreport. 1993;4(8):1027–1030. doi: 10.1097/00001756-199308000-00008
   PubMed Web of Science ®Google Scholar
• Thomsen LL, Kruuse C, Iversen HK, et al. A nitric oxide donor (nitroglycerin) triggers genuine migraine attacks. Eur J Neurol. 1994;1(1):73–80. doi: 10.1111/j.1468-1331.1994.tb00053.x
   PubMedGoogle Scholar
• Sances G, Tassorelli C, Pucci E, et al. Reliability of the nitroglycerin provocative test in the diagnosis of neurovascular headaches. Cephalalgia. 2004;24(2):110–119. doi: 10.1111/j.1468-2982.2004.00639.x
   PubMed Web of Science ®Google Scholar
• Eigenbrodt AK, Christensen RH, Ashina H, et al. Premonitory symptoms in migraine: a systematic review and meta-analysis of observational studies reporting prevalence or relative frequency. J Headache Pain. 2022;23(1):140. doi: 10.1186/s10194-022-01510-z
   PubMed Web of Science ®Google Scholar
• Afridi SK, Kaube H, Goadsby PJ. Glyceryl trinitrate triggers premonitory symptoms in migraineurs. Pain. 2004;110(3):675–680. doi: 10.1016/j.pain.2004.05.007
   PubMed Web of Science ®Google Scholar
• Maniyar FH, Sprenger T, Monteith T, et al. Brain activations in the premonitory phase of nitroglycerin-triggered migraine attacks. Brain. 2014;137(Pt 1):232–241. doi: 10.1093/brain/awt320
   PubMedGoogle Scholar
• Weiller C, May A, Limmroth V, et al. Brain stem activation in spontaneous human migraine attacks. Nat Med. 1995;1(7):658–660. doi: 10.1038/nm0795-658
   PubMed Web of Science ®Google Scholar
• Afridi SK, Giffin NJ, Kaube H, et al. A positron emission tomographic study in spontaneous migraine. Arch Neurol. 2005;62(8):1270–1275. doi: 10.1001/archneur.62.8.1270
   PubMedGoogle Scholar
• Bahra A, Matharu MS, Buchel C, et al. Brainstem activation specific to migraine headache. Lancet. 2001;357(9261):1016–1017. doi: 10.1016/S0140-6736(00)04250-1
   PubMed Web of Science ®Google Scholar
• Afridi SK, Matharu MS, Lee L, et al. A PET study exploring the laterality of brainstem activation in migraine using glyceryl trinitrate. Brain. 2005;128(Pt 4):932–939. doi: 10.1093/brain/awh416
   PubMed Web of Science ®Google Scholar
• Karsan N, Bose PR, Thompson C, et al. Headache and non-headache symptoms provoked by nitroglycerin in migraineurs: a human pharmacological triggering study. Cephalalgia. 2020;40(8):828–841. doi: 10.1177/0333102420910114
   PubMed Web of Science ®Google Scholar
• Christiansen I, Thomsen LL, Daugaard D, et al. Glyceryl trinitrate induces attacks of migraine without aura in sufferers of migraine with aura. Cephalalgia. 1999;19(7):660–667. discussion 626. doi: 10.1046/j.1468-2982.1999.019007660.x
   PubMed Web of Science ®Google Scholar
• Hansen J, Thomsen LL, Marconi R, et al. Familial hemiplegic migraine type 2 does not share hypersensitivity to nitric oxide with common types of migraine. Cephalalgia. 2008;28(4):367–375. doi: 10.1111/j.1468-2982.2008.01542.x
   PubMed Web of Science ®Google Scholar
• Hansen J, Thomsen LL, Olesen J, et al. Familial hemiplegic migraine type 1 shows no hypersensitivity to nitric oxide. Cephalalgia. 2008;28(5):496–505. doi: 10.1111/j.1468-2982.2008.01559.x
   PubMed Web of Science ®Google Scholar
• Hansen J, Thomsen LL, Olesen J, et al. Coexisting typical migraine in familial hemiplegic migraine. Neurology. 2010;74(7):594–600. doi: 10.1212/WNL.0b013e3181cff79d
   PubMed Web of Science ®Google Scholar
• Tassorelli C, Joseph SA, Buzzi MG, et al. The effects on the central nervous system of nitroglycerin–putative mechanisms and mediators. Prog Neurobiol. 1999;57(6):607–624. doi: 10.1016/S0301-0082(98)00071-9
   PubMed Web of Science ®Google Scholar
• Nielsen TH, Iversen HK, Tfelt-Hansen P, et al. Small arteries can be accurately studied in vivo, using high-frequency ultrasound. Ultrasound Med Biol. 1993;19(9):717–725. doi: 10.1016/0301-5629(93)90089-7
   PubMed Web of Science ®Google Scholar
• Dahl A, Russell D, Nyberg-Hansen R, et al. Effect of nitroglycerin on cerebral circulation measured by transcranial Doppler and SPECT. Stroke. 1989;20(12):1733–1736. doi: 10.1161/01.STR.20.12.1733
   PubMed Web of Science ®Google Scholar
• Hansen JM, Pedersen VI, Larsen VA, et al. Magnetic resonance angiography shows dilatation of the middle cerebral artery after infusion of glyceryl trinitrate in healthy volunteers. Cephalalgia. 2007;27(2):118–127. doi: 10.1111/j.1468-2982.2006.01257.x
   PubMed Web of Science ®Google Scholar
• Tegeler CH, Davidai G, Gengo FM, et al. Middle cerebral artery velocity correlates with nitroglycerin-induced headache onset. J Neuroimaging. 1996;6(2):81–86. doi: 10.1111/jon19966281
   PubMed Web of Science ®Google Scholar
• Iversen HK, Holm S, Friberg L, et al. Intracranial hemodynamics during intravenous infusion of glyceryl trinitrate. J Headache Pain. 2008;9(3):177–180. doi: 10.1007/s10194-008-0034-x
   PubMed Web of Science ®Google Scholar
• Ashina M, Tfelt-Hansen P, Dalgaard P, et al. Lack of correlation between vasodilatation and pharmacologically induced immediate headache in healthy subjects. Cephalalgia. 2011;31(6):683–690. doi: 10.1177/0333102410394672
   PubMed Web of Science ®Google Scholar
• Iversen HK. N-acetylcysteine potentiates nitroglycerin induced headache and dilatation of cranial but not extremity arteries. Clin Pharmacol Ther. 1992;52(2):125–133. doi: 10.1038/clpt.1992.121
   PubMed Web of Science ®Google Scholar
• Thomsen LL, Iversen HK, Brinck TA, et al. Arterial supersensitivity to nitric oxide (nitroglycerin) in migraine sufferers. Cephalalgia. 1993;13(6):395–399. doi: 10.1046/j.1468-2982.1993.1306395.x
   PubMed Web of Science ®Google Scholar
• Zanette EM, Agnoli A, Cerbo R, et al. Transcranial Doppler (TCD) after nitroglycerin in migraine without aura. Headache. 1991;31(9):596–598. doi: 10.1111/j.1526-4610.1991.hed3109596.x
   PubMed Web of Science ®Google Scholar
• Friberg L, Olesen J, Iversen HK, et al. Migraine pain associated with middle cerebral artery dilatation: reversal by sumatriptan. Lancet. 1991;338(8758):13–17. doi: 10.1016/0140-6736(91)90005-A
   PubMed Web of Science ®Google Scholar
• Iversen HK, Nielsen TH, Olesen J, et al. Arterial responses during migraine headache. Lancet. 1990;336(8719):37–39. doi: 10.1016/0140-6736(90)92339-J
   PubMed Web of Science ®Google Scholar
• Thomsen LL, Iversen HK, Olesen J. Cerebral blood flow velocities are reduced during attacks of unilateral migraine without aura. Cephalalgia. 1995;15(2):109–116. doi: 10.1046/j.1468-2982.1995.015002109.x
   PubMed Web of Science ®Google Scholar
• Zwetsloot CP, Caekebeke JFV, Ferrari MD. Lack of asymmetry of middle cerebral artery blood velocity in unilateral migraine. Stroke. 1993;24(9):1335–1338. doi: 10.1161/01.STR.24.9.1335
   PubMed Web of Science ®Google Scholar
• Schoonman GG, van der Grond J, Kortmann C, et al. Migraine headache is not associated with cerebral or meningeal vasodilatation – a 3T magnetic resonance angiography study. Brain. 2008;131(Pt 8):2192–2200. doi: 10.1093/brain/awn094
   PubMedGoogle Scholar
• Sorkin EM, Brogden RN, Romankiewicz JA. Intravenous glyceryl trinitrate (nitroglycerin). A review of its pharmacological properties and therapeutic efficacy. Drugs. 1984;27(1):45–80. doi: 10.2165/00003495-198427010-00003
   PubMed Web of Science ®Google Scholar
• Torfgård K, Ahlner J, Axelsson KL, et al. Tissue distribution of glyceryl trinitrate and the effect on cGMP levels in rat. Pharmacol Toxicol. 1989;64(4):379–382. doi: 10.1111/j.1600-0773.1989.tb00667.x
   Google Scholar
• Axelsson KL, Wikberg JE, Andersson RG. Relationship between nitroglycerin, cyclic GMP and relaxation of vascular smooth muscle. Life Sci. 1979;24(19):1779–1786. doi: 10.1016/0024-3205(79)90067-5
   PubMed Web of Science ®Google Scholar
• Nozaki K, Moskowitz MA, Maynard KI, et al. Possible origins and distribution of immunoactive nitric oxide synthase-containing nerve fibers in cerebral arteries. J Cereb Blood Flow Metab. 1993;13(1):70–79. doi: 10.1038/jcbfm.1993.9
   PubMed Web of Science ®Google Scholar
• Moncada S, Palmer RMJ, Higgs EA. Nitric oxide: physiology, pathophysiology and pharmacology. Pharmacol Rev. 1991;43(2):109–141.
   PubMed Web of Science ®Google Scholar
• Morris R, Southam E, Braid DJ, et al. Nitric oxide may act as a messenger between dorsal root ganglion neurones and their satellite cells. Neurosci Lett. 1992;137(1):29–32. doi: 10.1016/0304-3940(92)90290-N
   PubMed Web of Science ®Google Scholar
• Mellert ST, Gebhart GF. Nitric oxide (NO) and nociceptive processing in the spinal cord. Pain. 1993;52(2):127–136. doi: 10.1016/0304-3959(93)90124-8
   PubMed Web of Science ®Google Scholar
• Potter LR. Guanylyl cyclase structure, function and regulation. Cell Signal. 2011;23(12):1921–1926. doi: 10.1016/j.cellsig.2011.09.001
   PubMed Web of Science ®Google Scholar
• Wanstall JC, Homer KL, Doggrell SA. Evidence for, and importance of, cGMP-independent mechanisms with NO and NO donors on blood vessels and platelets. Curr Vasc Pharmacol. 2005;3(1):41–53. doi: 10.2174/1570161052773933
   PubMedGoogle Scholar
• Tanaka M, Zhang Y. Preclinical studies of posttraumatic headache and the potential therapeutics. Cells. 2022;12(1):155. doi: 10.3390/cells12010155
   PubMed Web of Science ®Google Scholar
• Stepien A, Chalimoniuk M. Level of nitric oxide-dependent cGMP in patients with migraine. Cephalalgia. 1998;18(9):631–634. doi: 10.1046/j.1468-2982.1998.1809631.x
   PubMed Web of Science ®Google Scholar
• D´amico D, Ferraris A, Leone M, et al. Increased plasma nitrites in migraine and cluster headache patients in interictal period: basal hyperactivity of L-arginine-NO pathway? Cephalalgia. 2002;22(1):33–36. doi: 10.1046/j.1468-2982.2002.00304.x
   PubMed Web of Science ®Google Scholar
• Fidan L, Yuksel L, Ymir T, et al. The importance of cytokines, chemokines and nitric oxide in pathophysiology of migraine. J Neuroimmunol. 2006;171(1–2):184–188. doi: 10.1016/j.jneuroim.2005.10.005
   PubMed Web of Science ®Google Scholar
• Sarchielli P, Alberti A, Codini M, et al. Nitric oxide metabolites, prostaglandins and trigeminal vasoactive peptides in internal jugular vein blood during spontaneous migraine attacks. Cephalalgia. 2000;20(10):907–918. doi: 10.1046/j.1468-2982.2000.00146.x
   PubMed Web of Science ®Google Scholar
• Gallai V, Floridi A, Mazzotta G, et al. L-arginine/nitric oxide pathway activation in platelets of migraine patients with and without aura. Acta Neurol Scand. 1996;94(2):151–160. doi: 10.1111/j.1600-0404.1996.tb07046.x
   PubMed Web of Science ®Google Scholar
• van der Kuy PH, Merkus FW, Lohman JJ, et al. Hydroxocobalamin, a nitric oxide scavenger, in the prophylaxis of migraine: an open, pilot study. Cephalalgia. 2002;22(7):513–519. doi: 10.1046/j.1468-2982.2002.00412.x
   PubMed Web of Science ®Google Scholar
• Lassen LH, Ashina M, Christiansen I, et al. Nitric oxide synthase inhibition in migraine. Lancet. 1997;349(9049):401–402. doi: 10.1016/S0140-6736(97)80021-9
   PubMed Web of Science ®Google Scholar
• Van der Schueren BJ, Lunnon MW, Laurijssens BE, et al. Does the unfavorable pharmacokinetic and pharmacodynamic profile of the iNOS inhibitor GW273629 lead to inefficacy in acute migraine? J Clin Pharmacol. 2009;49(3):281–290. doi: 10.1177/0091270008329548
   PubMed Web of Science ®Google Scholar
• Høivik HO, Laurijssens BE, Harnisch LO, et al. Lack of efficacy of the selective iNOS inhibitor GW274150 in prophylaxis of migraine headache. Cephalalgia. 2010;30(12):1458–1467. doi: 10.1177/0333102410370875
   PubMed Web of Science ®Google Scholar
• Juhasz G, Zsombok T, Modos EA, et al. NO-induced migraine attack: strong increase in plasma calcitonin gene-related peptide (CGRP) concentration and negative correlation with platelet serotonin release. Pain. 2003;106(3):461–470. doi: 10.1016/j.pain.2003.09.008
   PubMed Web of Science ®Google Scholar
• Juhasz G, Zsombok T, Jakab B, et al. Sumatriptan causes parallel decrease in plasma calcitonin gene-related peptide (CGRP) concentration and migraine headache during nitroglycerin induced migraine attack. Cephalalgia. 2005;25(3):179–183. doi: 10.1111/j.1468-2982.2005.00836.x
   PubMed Web of Science ®Google Scholar
• Kruuse C, Iversen HK, Jansen-Olesen I, et al. Calcitonin gene-related peptide (CGRP) levels during glyceryl trinitrate (GTN)-induced headache in healthy volunteers. Cephalalgia. 2010;30(4):467–474. doi: 10.1111/j.1468-2982.2009.01963.x
   PubMed Web of Science ®Google Scholar
• Van der Schueren BJ, Blanchard R, Murphy MG, et al. The potent calcitonin gene-related peptide receptor antagonist, telcagepant, does not affect nitroglycerin-induced vasodilation in healthy men. Br J Clin Pharmacol. 2011;71(5):708–717. doi: 10.1111/j.1365-2125.2010.03869.x
   PubMed Web of Science ®Google Scholar
• Tvedskov JF, Tfelt-Hansen P, Petersen KA, et al. CGRP receptor antagonist olcegepant (BIBN4096BS) does not prevent glyceryl trinitrate-induced migraine. Cephalalgia. 2010;30(11):1346–1353. doi: 10.1177/0333102410363491
   PubMed Web of Science ®Google Scholar
• Lassen LH, Thomsen LL, Kruuse C, et al. Histamine-1 receptor blockade does not prevent nitroglycerin induced migraine. Support for the NO-hypothesis of migraine. Eur J Clin Pharmacol. 1996;49(5):335–339. doi: 10.1007/BF00203773
   PubMed Web of Science ®Google Scholar
• Harder AVE, Onderwater GLJ, van Dongen RM, et al. Prostaglandin-E2 levels over the course of glyceryl trinitrate provoked migraine attacks. Neurobiol Pain. 2023;13:100112. doi: 10.1016/j.ynpai.2022.100112
   PubMedGoogle Scholar
• Iversen HK, Olesen J. Headache induced by a nitric oxide donor (nitroglycerin) responds to sumatriptan. A human model for development of migraine drugs. Cephalalgia. 1996;16(6):412–418. doi: 10.1046/j.1468-2982.1996.1606412.x
   PubMed Web of Science ®Google Scholar
• Schmetterer L, Wolzt M, Krejcy K, et al. Cerebral and ocular hemodynamic effects of sumatriptan in the nitroglycerin headache model. Clin Pharmacol Ther. 1996;60(2):199–205. doi: 10.1016/S0009-9236(96)90136-8
   PubMed Web of Science ®Google Scholar
• Luthringer R, Djupesland PG, Sheldrake CD, et al. Rapid absorption of sumatriptan powder and effects on glyceryl trinitrate model of headache following intranasal delivery using a novel bi-directional device. J Pharm Pharmacol. 2009;61(9):1219–1228. doi: 10.1211/jpp.61.09.0012
   PubMed Web of Science ®Google Scholar
• Fullerton T, Komorowski-Swiatek D, Forrest A, et al. The pharmacodynamics of sumatriptan in nitroglycerin-induced headache. J Clin Pharmacol. 1999;39(1):17–29. doi: 10.1177/00912709922007525
   PubMed Web of Science ®Google Scholar
• Tvedskov JF, Iversen HK, Olesen J, et al. Nitroglycerin provocation in normal subjects is not a useful human migraine model? Cephalalgia. 2010;30(8):928–932. doi: 10.1111/j.1468-2982.2009.02014.x
   PubMed Web of Science ®Google Scholar
• Costa A, Sances G, Bagetta G, et al. The effect of indomethacin on nitroglycerin-induced headache suggests an indirect role for nitric oxide in migraine. Cephalalgia. 1997;17:382.
   Google Scholar
• Caekebeke JFV, Ferrari MD, Zwetsloot CP, et al. Antimigraine drug sumatriptan increases blood flow velocity in large cerebral arteries during migraine attacks. Neurology. 1992;42(8):1522–1526. doi: 10.1212/WNL.42.8.1522
   PubMed Web of Science ®Google Scholar
• Tvedskov JF, Thomsen LL, Iversen HK, et al. The prophylactic effect of valproate on glyceryltrinitrate induced migraine. Cephalalgia. 2004;24(7):576–585. doi: 10.1111/j.1468-2982.2003.00720.x
   PubMed Web of Science ®Google Scholar
• Tfelt-Hansen P, Daugaard D, Lassen LH, et al. Prednisolone reduces nitric-oxide induced migraine. Eur J Neurol. 2009;16(10):1106–1111. doi: 10.1111/j.1468-1331.2009.02654.x
   PubMed Web of Science ®Google Scholar
• Shimomura T, Murakami F, Kotani K, et al. Platelet nitric oxide metabolites in migraine. Cephalalgia. 1999;19(4):218–222. doi: 10.1046/j.1468-2982.1999.019004218.x
   PubMed Web of Science ®Google Scholar
• Tvedskov JF, Thomsen LL, Iversen HK, et al. The effect of propranolol on glyceryltrinitrate-induced headache and arterial response. Cephalalgia. 2004;24(12):1076–1087. doi: 10.1111/j.1468-2982.2004.00796.x
   PubMed Web of Science ®Google Scholar
• Yuan H, White CS, Silberstein SD. Calcitonin gene-related peptide antagonists in the treatment of episodic migraine. Clin Pharmacol Ther. 2019;105(5):1121–1129. doi: 10.1002/cpt.1356
   PubMed Web of Science ®Google Scholar
• Tvedskov JF, IversenbHK, Olesen J. A double-blind study of SB-220453 (Tonerbasat) in the glyceryltrinitrate (GTN) model of migraine. Cephalalgia. 2004;24(10):875–882. doi: 10.1111/j.1468-2982.2004.00762.x
   PubMed Web of Science ®Google Scholar
• Cao Y, Zheng OJ. Tonabersat for migraine prophylaxis: a systematic review. Pain Physician. 2014;17(1):1–8. doi: 10.36076/ppj.2014/17/1
   PubMed Web of Science ®Google Scholar
• Arendt-Nielsen L, Nielsen TA, Gazerani P. Translational pain biomarkers in the early development of new neurotherapeutics for pain management. Expert Rev Neurother. 2014;14(3):241–254. doi: 10.1586/14737175.2014.884925
   PubMed Web of Science ®Google Scholar
• Sureda-Gibert P, Romero-Reyes M, Akerman S. Nitroglycerin as a model of migraine: Clinical and preclinical review. Neurobiol Pain. 2022;12:100105. doi: 10.1016/j.ynpai.2022.100105
   PubMedGoogle Scholar
• Ashina H, Schytz HW, Ashina M. CGRP in Human Models of Migraine. Handb Exp Pharmacol. 2019;255:109–120.
   PubMedGoogle Scholar
• Amin FM, Hougaard A, Schytz HW, et al. Investigation of the pathophysiological mechanisms of migraine attacks induced by pituitary adenylate cyclase-activating polypeptide-38. Brain. 2014;137(Pt 3):779–794. doi: 10.1093/brain/awt369
   PubMed Web of Science ®Google Scholar
• Lassen LH, Haderslev PA, Jacobsen VB, et al. CGRP may play a causative role in migraine. Cephalalgia. 2002;22(1):54–61. doi: 10.1046/j.1468-2982.2002.00310.x
   PubMed Web of Science ®Google Scholar
• Guo S, Christensen AF, Liu ML, et al. Calcitonin gene-related peptide induced migraine attacks in patients with and without familial aggregation of migraine. Cephalalgia. 2017;37(2):114–124. doi: 10.1177/0333102416639512
   PubMed Web of Science ®Google Scholar
• Guo S, Vollesen ALH, Olesen J, et al. Premonitory and nonheadache symptoms induced by CGRP and PACAP38 in patients with migraine. Pain. 2016;157(12):2773–2781. doi: 10.1097/j.pain.0000000000000702
   PubMed Web of Science ®Google Scholar
• Falkenberg K, Rønde Bjerg H, Yamani N, et al. Sumatriptan does not antagonize CGRP-Induced symptoms in healthy volunteers. Headache. 2020;60(4):665–676. doi: 10.1111/head.13747
   PubMed Web of Science ®Google Scholar